Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy
The release of this order may delay up to 4-6 weeks due to congestion at publisher’s warehouse.
Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy
Isocitrate Dehydrogenase Inhibitors in Cancer Chemotherapy presents an in-depth and up-to-date compilation of research on isocitrate dehydrogenase as drug target to be used as a sensitizing agent in chemotherapy. The book brings a combination of medicinal, biological and chemical points-of-view to fully cover the subject. It discusses topics such as IDH place in cellular metabolism, mutant IDH as drug target, mono- and poli-therapies based on IDH1/2 inhibitors, and IDH1/2 inhibitors in leukemia, gliomas and other brain tumors, and potential importance in gastrointestinal cancers. Additionally, it discusses isocitrate dehydrogenases as target for theranostics, therapeutic strategies and future perspectives.
This is a valuable resource for cancer researchers, oncologists and members of the biomedical field who are interested to learn more about IDH inhibitors and their potential as sensitizing agents for chemotherapy.
- Presents comprehensive and up-to-date review of current trends in design IDH inhibitors and their use as adjuvant therapy
- Contains summarized tables and schematic diagrams in each chapter to give a clear overview of the recent findings in a didactic manner
- Brings not only relevant information of current research but also new ideas and suggestions for further investigations to help advance the field
Shipping cost is based on weight. Just add products to your cart and use the Shipping Calculator to see the shipping price.
We want you to be 100% satisfied with your purchase. Items can be returned or exchanged within 30 days of delivery.